Pharma Blog Watch

XTL, DOV in Licensing Deal (Pharma Gazette)
In her blog, Gloria Gamat reports on news of a license agreement recently signed between XTL Biopharmaceuticals and DOV Pharmaceutical involving Bicifadine, a serotonin and norepinephrine reuptake inhibitor (SNRI) being developed for the treatment of neuropathic pain.

"Compared to the currently approved SNRI's, Bicifadine has a unique ratio of serotonin versus norepinephrine reuptake inhibition, which is weighted toward norepinephrine reuptake inhibition, providing a strong scientific rationale for using Bicifadine for the treatment neuropathic pain indications," according to the companies' release.